Matches in Wikidata for { <http://www.wikidata.org/entity/Q37137945> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- Q37137945 description "2008 թվականի ապրիլի 11-ին հրատարակված գիտական հոդված" @default.
- Q37137945 description "article científic" @default.
- Q37137945 description "article scientifique" @default.
- Q37137945 description "articolo scientifico" @default.
- Q37137945 description "artigo científico" @default.
- Q37137945 description "artículu científicu espublizáu en 2008" @default.
- Q37137945 description "bilimsel makale" @default.
- Q37137945 description "scientific article published on 11 April 2008" @default.
- Q37137945 description "vedecký článok" @default.
- Q37137945 description "vetenskaplig artikel" @default.
- Q37137945 description "videnskabelig artikel" @default.
- Q37137945 description "vědecký článek" @default.
- Q37137945 description "wetenschappelijk artikel" @default.
- Q37137945 description "wissenschaftlicher Artikel" @default.
- Q37137945 description "наукова стаття, опублікована у квітні 2008" @default.
- Q37137945 description "научни чланак" @default.
- Q37137945 description "مقالة علمية نشرت في 11 أبريل 2008" @default.
- Q37137945 name "Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review" @default.
- Q37137945 name "Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review" @default.
- Q37137945 name "Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review" @default.
- Q37137945 type Item @default.
- Q37137945 label "Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review" @default.
- Q37137945 label "Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review" @default.
- Q37137945 label "Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review" @default.
- Q37137945 prefLabel "Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review" @default.
- Q37137945 prefLabel "Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review" @default.
- Q37137945 prefLabel "Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review" @default.
- Q37137945 P1433 Q37137945-1BE4EA5B-617D-46C1-AAEC-8FDF26DADEE2 @default.
- Q37137945 P1476 Q37137945-E69056B7-B15A-4A05-9C86-A0B4B9DD5427 @default.
- Q37137945 P2093 Q37137945-2C46C1D0-0D87-43F4-995B-BED966BF1ACC @default.
- Q37137945 P2093 Q37137945-64188367-5B2D-473E-87A9-6CFCE66CC607 @default.
- Q37137945 P2093 Q37137945-723A549A-7546-406D-8997-EA3ADE520FA2 @default.
- Q37137945 P2093 Q37137945-DE1FCBDA-3FE8-43A3-8363-4A51A9EFDC45 @default.
- Q37137945 P2093 Q37137945-F230136F-D12D-4EAD-8AF5-A4869427E3F0 @default.
- Q37137945 P2860 Q37137945-9D8DFDC5-3A2D-4FBA-8A42-9D6969EAAA00 @default.
- Q37137945 P2860 Q37137945-A19AD7B2-0A15-41F4-96B2-9A3E0AC4A764 @default.
- Q37137945 P304 Q37137945-53058FFC-0F94-4F2D-BFE5-93DF2B3627B8 @default.
- Q37137945 P31 Q37137945-3283d5ae-bebe-4868-908e-c3c55d120a97 @default.
- Q37137945 P31 Q37137945-3de36391-c88c-4c82-a12b-ab94852d7198 @default.
- Q37137945 P31 Q37137945-BAC8BE9F-B2C4-4296-86BD-D871406ACC47 @default.
- Q37137945 P356 Q37137945-10DAFB4F-C928-4790-8745-DB3F1351C566 @default.
- Q37137945 P407 Q37137945-D24D5876-8C4F-4720-9607-AE28E079EF93 @default.
- Q37137945 P433 Q37137945-D175F13B-FDD3-4D19-AEF4-42FE93292F97 @default.
- Q37137945 P478 Q37137945-5900E1E4-B8B2-4615-B716-D601BBE72929 @default.
- Q37137945 P577 Q37137945-63E9FD30-21F3-475E-BA73-390745ECD68E @default.
- Q37137945 P698 Q37137945-CBC15C9C-DBB9-4B90-AFEE-F9B01074C5F3 @default.
- Q37137945 P921 Q37137945-46CA5A3B-EE91-4646-BD76-93859E57FBAB @default.
- Q37137945 P921 Q37137945-9CB40D5A-CEFC-4AAD-A527-398D78401214 @default.
- Q37137945 P921 Q37137945-FF75A6B8-E376-47C4-B017-D2BB5696BC9F @default.
- Q37137945 P356 J.1464-410X.2008.07668.X @default.
- Q37137945 P698 18410431 @default.
- Q37137945 P1433 Q4835773 @default.
- Q37137945 P1476 "Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review" @default.
- Q37137945 P2093 "Adrian Tookman" @default.
- Q37137945 P2093 "Bridget Candy" @default.
- Q37137945 P2093 "Louise Jones" @default.
- Q37137945 P2093 "Michael King" @default.
- Q37137945 P2093 "Rachael Williams" @default.
- Q37137945 P2860 Q33257160 @default.
- Q37137945 P2860 Q43812434 @default.
- Q37137945 P304 "426-431" @default.
- Q37137945 P31 Q13442814 @default.
- Q37137945 P31 Q7318358 @default.
- Q37137945 P31 Q815382 @default.
- Q37137945 P356 "10.1111/J.1464-410X.2008.07668.X" @default.
- Q37137945 P407 Q1860 @default.
- Q37137945 P433 "4" @default.
- Q37137945 P478 "102" @default.
- Q37137945 P577 "2008-04-11T00:00:00Z" @default.
- Q37137945 P698 "18410431" @default.
- Q37137945 P921 Q1504425 @default.
- Q37137945 P921 Q181257 @default.
- Q37137945 P921 Q184674 @default.